Reuters -- Abbott Laboratories Inc's second-quarter earnings fell 2.6 percent, with generic competition for its Depakote anti-seizure drug overshadowing strong sales of its Humira arthritis drug and its Xience heart stent.
Reuters -- Abbott Laboratories Inc's second-quarter earnings fell 2.6 percent, with generic competition for its Depakote anti-seizure drug overshadowing strong sales of its Humira arthritis drug and its Xience heart stent.
